Business
Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials
The Orthocell Ltd (ASX: OCC) share price is 17% higher this morning, after the company released positive results in its CelGro nerve repair study. At the time of writing, Orthocell shares are trading at 44 cents per share.
About Orthocell
Orthocell is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects.
The company’s regenerative medicine products include CelGro, a naturally derived collagen medical device for tissue repair. CelGro is designed for use in multiple indications to augment the surgical repair of tendons, bone, peripheral nerves and articular cartilage.
The product…
-
General12 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
Business21 hours agoWhat a rising Aussie dollar means for your ASX shares
-
Noosa News16 hours agoThree people rushed to hospital after Spring Hill unit fire
-
General22 hours agoAussies skipping dental, medical care to afford rent